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Abstract
The factors determining the functional avidity and its relationship with the broad heterogeneity of antiviral T cell responses
remain partially understood. We investigated HIV-specific CD8 T cell responses in 85 patients with primary HIV infection
(PHI) or chronic (progressive and non-progressive) infection. The functional avidity of HIV-specific CD8 T cells was not
different between patients with progressive and non-progressive chronic infection. However, it was significantly lower in
PHI patients at the time of diagnosis of acute infection and after control of virus replication following one year of successful
antiretroviral therapy. High-avidity HIV-specific CD8 T cells expressed lower levels of CD27 and CD28 and were enriched in
cells with an exhausted phenotype, i.e. co-expressing PD-1/2B4/CD160. Of note, a significant increase in the functional
avidity of HIV-specific CD8 T cells occurred in early-treated PHI patients experiencing a virus rebound after spontaneous
treatment interruption. This increase in functional avidity was associated with the accumulation of PD-1/2B4/CD160 positive
cells, loss of polyfunctionality and increased TCR renewal. The increased TCR renewal may provide the mechanistic basis for
the generation of high-avidity HIV-specific CD8 T cells. These results provide insights on the relationships between
functional avidity, viremia, T-cell exhaustion and TCR renewal of antiviral CD8 T cell responses.
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Introduction
CD8 T cells play a critical role in antiviral immunity and a large
number of studies in both human and murine models indicate that
virus-specific CD8 T cells are directly involved in the control of
virus replication and disease progression [1,2,3,4,5,6,7].
Functional avidity of T cells, also defined as antigen (Ag)
sensitivity, is thought to be a critical component of antiviral
immunity. Functional avidity reflects the ability of T cells to
respond to a low Ag dose and is determined by the threshold of Ag
responsiveness. There is a general consensus that high functional
avidity CD8 T-cell responses are of higher efficacy against cancers
[8] and acute virus infections [9]. However, their relevance in
chronic persistent virus infections and established tumors
[10,11,12] remains to be determined since conflicting results were
obtained in these contexts [13,14] as well as in HIV infection
[15,16,17,18,19]. HIV-specific CD8 T-cell responses in non-
progressive infection were associated with high avidity and
superior variants recognition [11,12,20,21], whereas other studies
indicated similar avidity between patients with progressive and
non-progressive chronic infection [16,18,19,22,23]. In this regard,
we have previously shown that polyfunctional virus-specific CD8
T-cell responses during chronic virus infections were predomi-
nantly of low functional avidity [24]. Furthermore, it is also well
established that high functional avidity T-cell responses preferen-
tially led to viral escape and T-cell clonal exhaustion
[10,24,25,26].
However, the factors determining the level of T-cell functional
avidity and its relationship with the phenotypic and functional
heterogeneity of T-cell responses are only partially understood
[15,16,17,18,19,22].
Functional avidity is based on the ability of T cells to respond
following stimulation with a cognate Ag and it is well established
that responding CD8 T cells are clonally heterogeneous (i.e.
oligoclonal) [27,28,29,30]. Therefore, the clonotypic composition
of the responding T-cell population (and its TCR diversity) can
influence functional avidity [27,28]. Indeed, we and others
reported that HIV-specific CD8 T cells responding to various
epitopes harbor a diverse TCR repertoire in chronically-infected
patients [31,32,33].
HIV-specific CD8 T cells in primary HIV infection (PHI) are
temporally associated with the initial control of viremia [1].
Lichterfeld and colleagues suggested that high-avidity HIV-specific
CD8 T-cell responses are present during early infection (defined as
HIV seroconversion within 6 months) and are then preferentially
lost overtime [33].
In the present study, we have performed a comprehensive cross-
sectional characterization of HIV-specific CD8 T-cell responses in
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patients with PHI or chronic (progressive and non-progressive)
HIV infection in both steady-state conditions as well as following
virus rebound. The primary observations of the present study
indicate that a) the functional avidity of HIV-specific CD8 T cells
is not different between patients with progressive and non-
progressive chronic infection, b) the functional avidity of HIV-
specific CD8 T cells is significantly lower in PHI patients as
compared to patients with chronic infections, c) increased
functional avidity is associated with T-cell exhaustion and lack
of expression of markers of co-stimulation, and d) great increase in
functional avidity is observed after virus rebound following
spontaneous interruption of antiretroviral therapy and is associ-
ated with increased TCR renewal.
Results
Lower functional avidity of HIV-specific CD8 T cell
responses during acute infection
We recruited 85 HIV-infected patients and performed a cross-
sectional analysis of the functional avidity of HIV-specific CD8 T-
cell responses. The distinct groups included a) 37 patients with
very early stage of acute infection (i.e. prior to seroconversion and
incomplete western blot; hereafter referred to as PHI), 39 patients
with progressive chronic infection (i.e. typical progressors; hereafter
referred to as CP) and 9 patients with non-progressive chronic
infection (i.e. LTNP) (Table S1). We first investigated the 115 HIV-
specific CD8 T-cell responses obtained in 26 untreated PHI (PHI-
B), 19 untreated CP (CP-B) patients and 9 LTNP (Fig. 1A–B). As
described in the Methods, blood mononuclear cells were
stimulated with decreasing concentrations of the cognate peptides
and the peptide dose able to induce half of the maximal response
(i.e. effect concentration 50%; EC50) was determined (Fig. 1A).
The results of this analysis indicated that the functional avidity
of HIV-specific CD8 T cells was lower in PHI-B as compared to
CP-B or LTNP patients (both P,0.0001; Fig. 1A–B) while there
was no difference between CP-B and LTNP (Fig. 1A–B).
However, there were no significant difference in the magnitudes
of HIV-specific CD8 T-cell responses among all groups (Fig. 1C)
and no significant association between the functional avidity and
the magnitude of HIV-specific CD8 T-cell responses (Fig. S1A).
Furthermore, the differences in functional avidity of HIV-specific
CD8 T cells between the different cohorts were not influenced by
distinct peptides/MHC class I associations, since these differences
remained significant when common epitopes (i.e. epitopes recog-
nized by patients from distinct cohorts) were analyzed (Fig. 1D).
Of note, the B*2705-KRWIILGLNK (i.e. KK10) epitope has been
previously reported as a protective epitope [28,34,35] and it was
one of the common epitopes recognized by CP-B and LTNP
patients. While the functional avidity of B*2705-KK10-specific
CD8 T-cell responses in CP-B and LTNP patients was almost
identical, it was rather low as compared to the other HIV-specific
CD8 T-cell responses from both groups (Fig. 1D).
Taken together, these results indicate a lack of association
between the functional avidity of HIV-specific CD8 T cells and
virus control consistently with the recent study from Chen and
colleagues [22]. Furthermore, the HIV-specific CD8 T-cell
responses in acute infection have lower functional avidity than in
chronic infection.
Characterization of HIV-specific CD8 T cell responses
disappearing after acute infection
It has been previously reported that high functional avidity
HIV-specific CD8 T-cell responses are selectively deleted early
after acute HIV infection [33]. We addressed this issue by
repeating the epitopes mapping in patients with acute infection
after one year of antiretroviral therapy (ART) (PHI-T1Y). Forty-
five HIV-specific CD8 T-cell responses were identified in PHI-B
patients using ICS. Among these 45 responses, 38 (85%) remained
detectable after one year of ART whereas 7 (15%) became
undetectable. Interestingly, at the time of acute infection, these 7
responses were already of lower magnitude as compared to the 38
responses which remained detectable (P = 0.03; Fig. 2A). Further-
more, the functional avidity of HIV-specific CD8 T-cell responses
at the time of acute infection was not different between the 7 lost
and the 38 remaining responses (P.0.05; Fig. 2A).
These results indicate that the minor proportion of HIV-specific
CD8 T-cell responses selectively lost after acute infection did not
have higher functional avidity.
Functional avidity of HIV-specific CD8 T cell responses
after one year of ART
It has been suggested that Ag load may influence the
responsiveness of HIV-specific CD8 T cells [36]. To address this
issue, we assessed whether the functional avidity of HIV-specific
CD8 T-cell responses would change after control of virus
replication, i.e. after 1 year of successful ART, in patients with
acute or chronic infection. Of note, 46 additional HIV-specific
CD8 T-cell responses were considered; 17 responses were
identified in the initial 26 PHI patients following re-mapping
after 1 year of ART and 29 responses were identified in 11
additional PHI patients only mapped after 1 year of ART. Both
magnitude and functional avidity of HIV-specific CD8 T-cell
responses generated during ART were similar to those measured
at baseline (Fig. 2A). Furthermore, PHI patients were treated
either with ART alone or with ART+CyclosporinA (CsA) but
CSA treatment had no significant impact on the magnitude or
the functional avidity of HIV-specific CD8 T-cell responses (Fig.
S2).
The functional avidity of the same HIV-specific CD8 T-cell
responses measured longitudinally either prior to ART or after 1
year of ART remained stable in both PHI and CP patients (both
Author Summary
CD8 T cells directed against virus are complex and
functionally heterogeneous. One relevant component of
CD8 T cells is their functional avidity which reflects their
sensitivity to cognate antigens, i.e. how prone T cells are to
respond when they encounter low doses of antigens. In
patients with chronic and established HIV infection, we
observed that the sensitivity of HIV-specific CD8 T cells was
not different between patients with progressive or non-
progressive disease. In contrast, the sensitivity of HIV-
specific CD8 T cells was significantly lower in patients with
early and recent HIV infection. Furthermore, CD8 T cells of
high avidity were preferentially associated with a state of
functional impairment known as exhaustion. Of interest,
some patients treated with antiretroviral therapy during
acute infection spontaneously interrupted their treatment
and experienced a rebound of virus. In these patients, the
avidity of HIV-specific CD8 T cells increased and this
increase was associated to stronger cell exhaustion and
greater renewal of the population of antiviral CD8 T cells,
thus potentially providing the mechanistic basis for the
generation of high-avidity CD8 T cells. Overall, our data
suggest that rapid perturbation in viremia levels drove
increases in the functional avidity of HIV-specific CD8 T
cells.
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P.0.05; Fig. 2B). Furthermore, the lack of significant effect of
ART on the functional avidity of HIV-specific CD8 T cells was
also confirmed in non-longitudinal, independent, T-cell responses
from PHI or CP patients (both P.0.05; Fig. 2C). Therefore, HIV-
specific CD8 T-cell responses remained of lower avidity
(P = 0.0003) in PHI-T1Y as compared to CP-T1Y patients
(Fig. 2D). Consistently with the above-mentioned analyses
performed in the untreated groups, differences in functional
avidity of HIV-specific CD8 T cells between PHI-T1Y and CP-
T1Y were not related to distinct peptide-MHC class I associations
since the differences remained significant also when common
epitopes were considered (P = 0.0003; Fig. 2E).
All together, these observations indicate that even after control
of virus replication HIV-specific CD8 T-cell responses from
patients with acute HIV infection remain of lower avidity as
compared to patients with chronic infection.
Functional and phenotypic profiles of HIV-specific CD8 T
cells during acute and chronic HIV infections
We then assessed the functional profile of HIV-specific CD8 T
cells from PHI-B, CP-B and LTNP patients. Although, the
magnitudes of HIV-specific CD8 T-cell responses were not
significantly different between PHI-B, CP-B and LTNP (Fig. 1C),
perforin expression was significantly (P#0.001) higher in HIV-
specific CD8 T cells from PHI-B patients as compared to CP-B or
LTNP (Fig. S1B and 3A). As previously shown [37,38], HIV-
specific CD8 T cells from LTNP contained more IL-2, whereas
those from CP-B patients were mostly composed of single IFN-c-
producing cells (both P,0.0001; Fig. S1B and 3A).
We then performed a phenotypic characterization of HIV-
specific CD8 T-cell responses and monitored CD27 and CD28
expression to assess co-stimulation and PD-1, 2B4 and CD160
expression to assess T-cell activation and exhaustion. For these
analyses, only HIV-specific CD8 T cells detectable using cognate
peptide-MHC class I multimers (Table S2) were taken into
consideration. Regarding T-cell co-stimulation, HIV-specific CD8
T cells from PHI-B expressed a higher proportion of
CD27+CD28+ cells than those from CP-B (P = 0.02) or LTNP
(P = 0.003) patients (Fig. S1C and 3B). Also, analyses of the
expression of co-inhibitory receptors indicated that HIV-specific
CD8 T cells from CP-B and LTNP were both composed of
significantly higher proportions of PD-1+2B4+CD160+ (P,0.006
and P,0.025, respectively) or PD-122B4+CD160+ (P,0.025 and
P,0.0001, respectively) as compared to PHI-B (Fig. S1D and 3C).
HIV-specific CD8 T cells from PHI-B mostly (about 70%) lacked
all three markers or expressed 2B4 alone (all P,0.006; Fig. 3C)
and expressed lower frequency and intensity of PD-1 as compared
to CP-B (both P,0.002; data not shown).
These data suggest that HIV-specific CD8 T cells from patients
with acute and chronic infection are functionally and phenotyp-
ically distinct.
Association between the functional avidity and the
phenotypic and functional heterogeneity of HIV-specific
CD8 T cells
We then assessed the association between functional avidity and
the expression of co-stimulatory or co-inhibitory receptors. The
functional avidity of HIV-specific CD8 T cells was negatively
Figure 1. Functional avidity of HIV-specific CD8 T-cell responses. A. Representative examples of functional avidity of HIV-specific CD8 T-cell
responses in patients with acute (PHI-B-09; circles), chronic progressive (CP-B-08; squares) or chronic non-progressive (LTNP-2082; triangles) infection
after stimulation with decreasing concentrations of B*0801-EIYKRWII peptides. The dashed line corresponds to half of the maximal response allowing
the extrapolation of the 50% effect concentration (EC50). B. Cumulative analysis of the functional avidity of HIV-specific CD8 T cells during acute (PHI-
B), untreated chronic progressive (CP-B) and non-progressive infection (LTNP). Medians and interquartile ranges are shown and each point represents
one HIV-specific CD8 T-cell response. C. Cumulative analysis of the frequency of HIV-specific CD8 T cells during acute (PHI-B), untreated chronic
progressive (CP-B) and non-progressive infection (LTNP). D. Functional avidity of HIV-specific CD8 T-cell responses against common optimal epitopes
recognized by patients with acute (PHI-B), chronic progressive (CP-B) or not progressive (LTNP) infections. The red line (right panel) shows the
functional avidity of B*2705-KRWIILGLNK (KK10)-specific CD8 T-cell response.
doi:10.1371/journal.ppat.1003423.g001
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correlated to the proportion of CD27+CD28+ cells (P = 0.01;
Fig. 4A) and directly correlated to the proportion of cells co-
expressing PD-1/2B4/CD160 (P = 0.005; Fig. 4B).
Furthermore, we performed correlations and rank correlation’s
matrix to explore the partial associations of variables and to assess
the dependency and potential hidden effect of confounding
variables in pairs associations. These analyses indicated that the
proportions of CD27+CD28+ and of PD-1+2B4+CD160+ HIV-
specific CD8 T cells were not significantly dependent on each
other. This allowed us to perform a regression model analysis and
to postulate that the functional avidity of HIV-specific CD8 T cells
may be a linear function of the two aforementioned explained
variables (after log10 transformation). Interestingly, this regression
analysis indicated that about 28% of the functional avidity of HIV-
specific CD8 T cells was explained by a combination of the
proportion of CD27+CD28+ and of PD-1+2B4+CD160+ CD8 T
Figure 2. Analysis of the functional avidity of HIV-specific CD8 T-cell responses after one year of ART. A. Comparison of the magnitude
(left panel) and functional avidity (right panel) of HIV-specific CD8 T-cell responses measured during acute infection (PHI-B) between responses which
remained detectable (referred to as ‘‘maintained’’) and those which became undetectable (referred to as ‘‘lost’’) after one year of ART. Seventeen HIV-
specific CD8 T-cell responses which were absent at baseline and developed during ART are also shown. B. Longitudinal matched-paired analysis of
the functional avidity of HIV-specific CD8 T-cell responses measured before (-B) or after (-T1Y) 1 year of ART in patients with acute (PHI) or chronic
progressive (CP) HIV infection. C. Functional avidity of independent HIV-specific CD8 T-cell responses detected in untreated (-B) or treated (-T1Y)
patients with acute (PHI) or chronic progressive (CP) HIV infection. D. Functional avidity of HIV-specific CD8 T cells from patients with acute (PHI) or
chronic progressive (CP) both after one year of ART (T1Y). E. Functional avidity of HIV-specific CD8 T-cell responses against common optimal epitopes
recognized either by patients treated for 1 year since acute infection (PHI-T1Y) or treated for 1 year since chronic progressive infection (CP-T1Y).
doi:10.1371/journal.ppat.1003423.g002
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cells (P = 0.0013; data not shown). We did not, in contrast, observe
any significant correlation between the functional avidity of HIV-
specific CD8 T cells and their functional profile.
Overall, these observations indicate that high-avidity HIV-
specific CD8 T-cell responses are preferentially composed of cells
lacking the expression of co-stimulatory molecules but co-
expressing high levels of co-inhibitory receptors. However, the
functional avidity can only be partially predicted from the
expression of co-stimulatory or co-inhibitory molecules.
Qualitative changes of HIV-specific CD8 T cells in patients
experiencing a virus rebound following treatment
interruption
We then performed a longitudinal analysis to investigate the
effect of changes in viremia levels on HIV-specific CD8 T cells. To
address this issue, we longitudinally monitored HIV-specific CD8
T cells in two distinct models: a) in conditions of viremia below the
limit of detection, i.e. viremia ,50 HIV RNA copies/ml of plasma
(in patients successfully treated by ART) and b) in conditions of
rapid and major changes in viremia occurring in patients
experiencing virus rebound following spontaneous treatment
interruption (TI) (Fig. 5A). In particular, we evaluated HIV-
specific CD8 T-cell responses in PHI-T1Y and compared them
with those after 5 years (PHI-T5Y) of uninterrupted successful
ART or after TI (PHI-ATI) (Fig. 5A). Nine out of the 37 patients
identified during acute infection spontaneously interrupted ART.
These patients were treated since PHI for $1 year (mean6SE
131615 weeks) and all had undetectable viremia (,50 HIV RNA
copies/ml) at the time of TI. After TI, all patients experienced a
virus rebound with an average plasma viremia of 5.18 log10 HIV
RNA copies/ml.
The functional profile of HIV-specific CD8 T-cell responses at
the time of TI was different from that of baseline. HIV-specific
CD8 T cells in PHI-T1Y were mostly polyfunctional (associated to
a large fraction of IL-2-producing cells and little perforin)
(P,0.0001; Fig. 5B–C) as compared to the typical effector profile
(Fig. 3A) observed in PHI-B. In patients remaining on ART, HIV-
specific CD8 T cells became more polyfunctional (i.e. further
shifted toward IL-2 production) after 5 years of ART as compared
to 1 year of ART (Fig. 5B–C). Conversely, in patients interrupting
ART, as shown for patient #1023 who interrupted ART after two
Figure 3. Functional profile and expression of co-stimulatory molecules and of co-inhibitory receptors of HIV-specific CD8 T-cell
responses during acute and chronic HIV infections. Analysis of the functional profile (A), of the expression of CD27 and CD28 (B) and of the
expression of 2B4, CD160 and PD-1 (C) in HIV-specific CD8 T cells in patients with acute (PHI-B), untreated chronic progressive (CP-B) or non-
progressive (LTNP) HIV infection. Representative examples of the distinct flow cytometry panels are shown in Fig. S1B-D. Regarding the functional
profile (A), although TNF-a was detected, analyses are restricted to the expression of IFN-c, IL-2 and perforin for clarity. All possible combinations of
the distinct markers are shown on the x axis, whereas the percentages of the distinct cell subsets within virus-specific CD8 T cells are shown on the y
axis. The pie charts summarize the data, and each slice corresponds to a certain combination of molecules. Colors in the pie charts are based on the
colored boxes at the bottom of the panel.
doi:10.1371/journal.ppat.1003423.g003
Figure 4. Associations between functional avidity of HIV-specific CD8 T-cell responses and other immunological parameters.
Associations between the functional avidity of HIV-specific CD8 T-cell responses and the frequency of HIV-specific CD8 T cells co-expressing CD28
and CD27 (A) or PD-1, 2B4 and CD160 (B).
doi:10.1371/journal.ppat.1003423.g004
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years of treatment and experienced a virus rebound of 122’000
HIV RNA copies/ml, the proportion of HIV-specific CD8 T cells
co-producing IFN-c and IL-2 decreased (Fig. 5A–B). Cumulative
analyses confirmed the significant (P,0.01) decrease in poly-
functionality of HIV-specific CD8 T-cell responses after TI and
the significant (P = 0.03) increase in polyfunctionality of HIV-
specific CD8 T-cell responses from patients who remained on
ART (Fig. 5C).
Then we determined PD-1 (as well as 2B4 and CD160)
expression in a subset of PHI-ATI and PHI-T5Y patients with
known HIV-specific CD8 T-cell responses using cognate peptide-
MHC class I multimers (Table S2). As shown in the representative
flow cytometry profiles from patients #1017 and #1023, PD-1
expression increased in patient #1023 who interrupted ART but
not in patient #1017 who remained on ART (Fig. 5D). Along the
same line, the proportion of triple PD-1+2B4+CD160+ HIV-
specific CD8 T cells also increased in patient #1023 but not in
patient #1017 (Fig. 5F). Cumulative analyses confirmed that PD-1
expression as well as the proportion of cells co-expressing PD-1/
2B4/CD160 in HIV-specific CD8 T cells were significantly
increased in patients who interrupted ART (both P = 0.03; Fig. 5E
and 5G). No increase in PD-1 expression or in the co-expression of
PD-1/2B4/CD160, however, was observed in the patients who
remained on ART (both P.0.05; Fig. 5E and G). Finally,
consistently with the differences in the functional profile of HIV-
specific CD8 T-cell responses between patients who did or did not
interrupt ART (Fig. 5B–C), we observed that the proportion of
dual IFN-c/IL-2-producing HIV-specific CD8 T cells was
negatively correlated with the proportion of cells co-expressing
PD-1/2B4/CD160 (P = 0.009; data not shown).
Figure 5. Qualitative changes of HIV-specific CD8 T cells in patients experiencing a virus rebound following treatment interruption.
A. Longitudinal analysis of the CD4 T-cell counts and HIV viremia of 2 representative HIV-infected patients (#1017 and#1023) treated with ART since
acute infection. Patient #1017 remained on ART, whereas patient#1023 spontaneously interrupted ART after 119 weeks (orange box). B. Functional
profiles of B*0702-GPGHKARVL-specific CD8 T cells from patients#1017 and#1023 analyzed at two distinct time-points corresponding to weeks 48 and
300 (identified by the arrows in A). C. Cumulative analysis of the functional profile of HIV-specific CD8 T-cell responses on the basis of the expression
of IFN-c, IL-2 and perforin in patients with acute (PHI) infection after one year of ART (-T1Y) and after either treatment interruption (-ATI) or after five
years of ART (-T5Y). Matched-paired HIV-specific CD8 T-cell responses are considered for the comparison between T1Y and ATI or between T1Y and
T5Y. Although TNF-a was also detected, analysis is restricted to the expression of IFN-c, IL-2 and perforin for clarity. All possible combinations of IFN-
c, IL-2 and perforin are shown on the x axis, whereas the percentages of the distinct cell subsets within HIV-specific CD8 T cells are shown on the y
axis. The pie charts summarize the data, and each slice corresponds to a certain combination of functions. Colors in the pie charts are based on the
colored boxes at the bottom of the panel. D. PD-1 expression in B*0702-GPGHKARVL-specific CD8 T cells in patients#1017 and #1023 measured at the
two time-points identified with arrows in A. E. Mean fluorescence intensity (MFI) of PD-1 expression in HIV-specific CD8 T cells measured in patients
with acute (PHI) HIV infection after 1 year of ART (-T1Y) and after either treatment interruption (-ATI, left panel) or after five years of ART (-T5Y, right
panel). F. Proportion of PD-1+2B4+CD160+ cells in B*0702-GPGHKARVL-specific CD8 T cells in patients #1017 and #1023 measured at the two time-
points identified with arrows in A. G. Proportion of PD-1+2B4+CD160+ cells in HIV-specific CD8 T cells measured in patients with acute (PHI) HIV
infection after 1 year of ART (-T1Y) and after either treatment interruption (-ATI, left panel) or after five years of ART (-T5Y, right panel).
doi:10.1371/journal.ppat.1003423.g005
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These data indicate that major changes of viremia levels in TI
patients caused reduction of polyfunctional HIV-specific CD8 T
cells and were associated with an increased level of exhaustion.
Increase in functional avidity of HIV-specific CD8 T cells
following TI
We then analyzed the effects of virus rebound following TI on
the functional avidity of HIV-specific CD8 T cells.
As shown for patient #1023, the functional avidity of
B*0701-GPGHKARVL- and A*0301-RLRPGGKKK-specific CD8 T-
cell responses significantly increased after TI (ATI) as compared
to pre-TI (PTI) (Fig. 6A). Furthermore, an additional HIV-
specific CD8 T-cell response against B*0701-IPRRIRQGL, which
was below the detection level PTI, was observed ATI (Fig. 6A).
Cumulative analyses confirmed the increase in functional avidity
of HIV-specific CD8 T cells occurring ATI (P = 0.007; Fig. 6B)
and also indicated that new responses generated following virus
rebound were of high avidity (P = 0.04; Fig. 6B). Consistently, no
significant (P.0.05) differences in functional avidity were
observed during the same period when a similar analysis was
performed in HIV-specific CD8 T-cell responses from patients
who did not interrupt ART (i.e. for an average of 4 years; Fig. 6B).
Furthermore, the functional avidity of HIV-specific CD8 T-cell
responses ATI was in the same range as compared to those
observed in CP patients (data not shown). Of note, consistently
with the increase in the co-expression of co-inhibitory molecules
occurring in patients experiencing virus rebound (Fig. 5F–G), we
observed a positive association (P = 0.02) between the fold
increase in functional avidity of HIV-specific CD8 T cells and
the fold increase in the proportion of PD-1+2B4+CD160+ HIV-
specific CD8 T cells (Fig. 6C).
Of interest, we performed a comprehensive statistical modeling
of the changes in functional avidity of HIV-specific CD8 T cells
and used mixed-effect linear models [39,40] to assess the evolution
of functional avidity as a function of time and virus rebound.
For this analysis, all longitudinal measures (n = 231) of
functional avidity were included. The statistical model revealed
that the interaction between avidity and time was not significant in
steady-state conditions, i.e. neither in patients on ART (Fig. 6D;
red line), nor in patients off ART (Fig. 6D; green line). In both
conditions, an increase of 0.013 units per month was determined
but did not reach statistical significance (P = 0.05; Fig. 6D), thus
indicating that functional avidity does not significantly change
under steady-state circumstances. However, we found a significant
(P = 0.013) interaction between functional avidity and virus
rebound. An immediate increase of functional avidity of HIV-
specific CD8 T cells of about 1 order of magnitude (0.95 units)
occurred directly after TI (Fig. 6D, grey dashed lines) and was not
related to the duration of ART prior to TI.
These observations indicated that the functional avidity of HIV-
specific CD8 T cells is stable overtime in steady-state conditions
Figure 6. Increase in functional avidity of HIV-specific CD8 T cells following treatment interruption. A. Functional avidity of
B*0702-GPGHKARVL- and A*0301-RLRPGGKKK-specific CD8 T cells from patient #1023 before (-PTI) and after (-ATI) treatment interruption (TI) and analysis
of the functional avidity of B*0702-IPRRIRQG-specific CD8 T-cell response, which was undetectable before TI. B. Cumulative matched-paired analysis of
the functional avidity of HIV-specific CD8 T-cell responses in patients treated during acute HIV infection (PHI) before (-PTI) or after treatment
interruption (-ATI) and in PHI patients after 1 (-T1Y) or 5 years (-T5Y) of uninterrupted ART. Twenty new HIV-specific CD8 T-cell responses generated
ATI (New-ATI) within the same patients are also shown. C. Association between the fold increase in avidity of HIV-specific CD8 T-cell responses and
the fold increase in the proportion of HIV-specific CD8 T cells co-expressing PD-1, 2B4 and CD160. D. Mixed-effect linear models were used to assess
the evolution of functional avidity as a function of time and virus rebound, as detailed in the Methods. Solid lines represent the lack of significant
increase in avidity overtime in patient ON (red line) or OFF (green line) ART, whereas the dashed lines represent the immediate increase of functional
avidity occurring after treatment interruption.
doi:10.1371/journal.ppat.1003423.g006
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regardless of viremia levels, but does increase after rapid increase
in viremia levels associated with virus rebound.
Association between CDR3 renewal and increase in
functional avidity of HIV-specific CD8 T cells
We recently demonstrated that the global CD8 TCR repertoire
of virus-specific CD8 T cells was diverse and subjected to
continuous renewal [32]. We then evaluated the TCR repertoire
in PHI patients experiencing a virus rebound following TI. For
this purpose, we measured CDR3 diversity and the percentage of
renewal of HIV-specific CD8 T cells and compared those to the
changes in functional avidity of HIV-specific CD8 T cells
occurring before and after virus rebound.
As shown for patient #1023 (Fig. 5A), TRBV usage and CDR3
size pattern were analyzed for B*0701-GPGHKARVL-specific CD8 T
cells at week (W) 18, W96 and W125 (Fig. S3A–B). Using our
previously-described model to determine CDR3 renewal [32], we
calculated a renewal of 76% between W18 and W96 (i.e. on ART)
and a renewal of 82% between W96 and W125 (i.e. after TI).
Cumulative analyses confirmed a significantly (P = 0.008) higher
CDR3 renewal of HIV-specific CD8 T cells after virus rebound
than in steady-state condition, i.e. during treatment (Fig. 7A).
Interestingly, the level of CDR3 renewal was directly associated
(P = 0.036) with the extent of increase in functional avidity of HIV-
specific CD8 T cells (Fig. 7B).
Taken together, these observations suggest that increase in
CDR3 renewal may contribute to the increase in functional avidity
of HIV-specific CD8 T cells occurring after virus rebound.
Discussion
T-cell functional avidity reflects the ability of T cells to respond
to various concentrations of Ag and may be assessed ex vivo
through a quantification of a biological function such as IFN-c
production, cytotoxic activity or proliferation capacity. Several
parameters concur to determine the threshold of T-cell respon-
siveness. These include: a) the affinity of the TCR for the peptide-
MHC (pMHC) molecule, i.e. the strength of the interaction
between the TCR and pMHC [41,42], b) the density of pMHC-
TCR interactions (reflecting both the amount of Ag and the ability
of Ag presenting cells (APC) to present Ags) [43,44,45,46], c) the
expression of co-stimulatory and co-inhibitory molecules by T cells
and APC [47], and d) the T-cell distribution and composition of
signaling molecules [44,48]. However, the factors determining
functional avidity and the relationship between functional avidity
and the heterogeneity of T-cell responses are not well understood.
In the present study, we comprehensively investigated the
functional avidity of HIV-specific CD8 T-cell responses in a cross-
sectional study of different cohorts of HIV-infected patients. The
evaluation of the functional avidity of HIV-specific CD8 T cells
was based on optimal epitopes, i.e. epitopes not necessarily
corresponding to the autologous virus sequences. Since pMHC/
TCR affinity is one of the parameters potentially influencing the
functional avidity [49,50], a mismatch between the epitope
sequences and the TCR or the MHC may impact the
determination of avidity. However, the same strategy was used
throughout all cohorts of HIV-infected patients, thus minimizing
the potential biases in our observations.
HIV-specific CD8 T cells generated during acute infection were
of lower functional avidity as compared to those from patients with
chronic progressive or non-progressive infection. These differences
were not biased by distinct peptide-HLA associations and
remained significant after ART-induced control of virus replica-
tion. In addition, a preferential deletion of HIV-specific CD8 T-
cell responses of higher avidity was not observed, as previously
described in a cohort of early HIV infection [33]. The discrepancy
between our and the previous study may be explained by
differences in the individual cohorts as well as by the fact that
all the 37 patients received ART at the time of diagnosis of PHI in
our study, whereas only 5 of the 10 patients in Lichterfeld’s study
received ART [33]. Our results also indicated that the minor
proportion of HIV-specific CD8 T-cell responses lost after acute
infection had an initial lower magnitude rather than a higher
avidity.
Furthermore, consistently with previous studies [16,18,19,
22,23,51], there were no significant differences in the functional
avidity of HIV-specific CD8 T-cell responses from chronic
progressive and non-progressive infection. These observations
suggest that T-cell functional avidity does not represent a correlate
of virus control, at least in the context of chronic and persistent
virus infections. Along the same line, HIV-specific CD8 T-cell
responses commonly associated with virus control [52], i.e. HLA-
B*27-, B*57- or B*5801-restricted T-cell responses, were consis-
tently found in the lower range of functional avidity (data not
shown). These observations do not support previous studies
showing a relationship between higher avidity T-cell responses
Figure 7. Increased CDR3 renewal of HIV-specific CD8 T cells following treatment interruption and association with functional
avidity. A. Percentage of CDR3 renewal of HIV-specific CD8 T cells before (under treatment) and after treatment interruption (TI). CDR3 diversity and
renewal were determined as described [32]. Example of TRBV usage and CDR3 size pattern analysis of B*0702-GPGHKARVL-specific CD8 T cells in patient
#1023 at week 18, 96 and 125 are shown in Fig. S3. B. Association between the percentage of CDR3 renewal and changes in the functional avidity of
HIV-specific CD8 T cells.
doi:10.1371/journal.ppat.1003423.g007
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and better virus control [11,12,20,21,53,54]. One potential
explanation is that in most of these studies, specific T-cell epitopes
(e.g. TW10 or KK10) were considered predominantly in
individuals with non-progressive infection. Of note, consistently
with our study, Chen and colleagues recently demonstrated that
KK10-specific CD8 T-cell responses in elite controllers showed
better virus control and broader viral recognition but similar
functional avidity as compared to progressors [22]. They also
confirmed the overall lack of difference in the functional avidity of
HIV-specific CD8 T cells between patients with progressive and
non-progressive infection [22].
Taken together, these observations suggest an association
between higher avidity T-cell responses and chronic HIV
infection.
Of note, we also assessed the relationship between T-cell
functional avidity and the expression of markers of exhaustion. It is
important to underscore that HIV-specific CD8 T cells which had
higher avidity in chronic infection expressed also higher levels of
exhaustion markers. Therefore, these results further indicate that
higher functional avidity does not correlate with better virus
control but rather with the status of cells activation/exhaustion.
We also determined the impact of the expression of costimu-
lation (i.e. CD27 and CD28) and exhaustion markers (i.e. PD-1,
CD160 and 2B4) on the levels of functional avidity in HIV-specific
CD8 T cells using a regression model. The regression model
indicated that the expression of the above markers only partially
accounts for the establishment of the functional avidity of HIV-
specific CD8 T cells, thus indicating that additional factors may
contribute to determine the levels of functional avidity.
The lower avidity of HIV-specific CD8 T cells in PHI patients
may also be potentially explained by the fact that patients were
identified very early in the course of infection and received ART
within 24 hours. Therefore, one cannot exclude the possibility that
this early control of virus replication blunted the natural evolution
and maturation of the immune response, as previously shown for
T- and B-cell responses [55,56,57]. Consistently, it was also shown
in mice that functional avidity of antiviral CD8 T cells
continuously increased (avidity maturation) during the first month
of infection [58].
In this regard, when patients treated during PHI experienced a
virus rebound, the functional avidity of HIV-specific CD8 T-cell
responses significantly increased. The mixed-effect linear model
we used indicated a punctual increase of about one order of
magnitude following virus rebound. However, there was no
quantitative correlation between either the peak or the steady-state
of the virus rebound and the increase in avidity.
Several mechanisms were proposed to modulate T-cell func-
tional avidity maturation including: 1) the formation of clusters
comprising several TCRs and other molecules able to reinforce the
immunological synapses [59,60,61], 2) the optimization of the
signal transduction machinery such as an increase in the amount
of and in the basal phosphorylation levels of signaling molecules
[62,63] and 3) a selective expansion of high TCR avidity clones
and/or the loss of clones with low TCR avidity [33,64,65,66,67].
We cannot exclude that the same mechanisms may also contribute
to explain the increase in avidity observed following treatment
interruption and virus rebound.
Interestingly, we showed that TCR renewal was also signif-
icantly higher following virus rebound and associated with an
increase in T-cell functional avidity. Therefore, our data indicate a
potential role of TCR renewal in the modulation of the levels of
functional avidity. However, our results do not distinguish between
the recruitment of new clones, selective expansion of pre-existing
high-avidity clones or depletion of low-avidity clones since the
study was performed at the population level.
Taken together, these results support the following model.
HIV-specific CD8 T cells of lower functional avidity are
generated during primary immune responses; then, persistence of
detectable viremia drives an increase in functional avidity as
supported by the major increase in functional avidity associated
with the sudden increment in viremia levels; the increase in
viremia levels is also associated with massive TCR renewal which,
in turn, causes the generation/selection of T-cell clones with
higher functional avidity.
These results provide insights on the relationships between
functional avidity, viremia, T-cell exhaustion and TCR renewal of
antiviral CD8 T-cell responses.
Methods
Ethics statement
These studies were approved by the Institutional Review Board
of the Centre Hospitalier Universitaire Vaudois and all subjects
gave written informed consent.
Study groups
Seventy-six patients with primary (PHI) or progressive chronic
(CP) HIV infection were enrolled. Diagnosis of PHI included the
presence of an acute clinical syndrome, a negative HIV antibody
test, a positive test for HIV RNA in plasma, and#3 positive bands
in a Western blot. All PHI patients started ART alone or
ART+CsA within 72 h as described [68] and were followed for up
to 10 years. Patients with chronic progressive (CP) HIV infection
were infected for more than a year, were ART-naı¨ve at the time of
inclusion, had $400 CD4 T-cells/ml, $5000 plasma HIV RNA
copies/ml and were directly treated with ART upon diagnosis as
described [69,70]. Four CP patients were investigated both prior
to (BSL) and then after 1 year of ART (T1Y). Furthermore, 9
additional HIV-infected patients with non-progressive disease, i.e.
LTNP, as defined by documented HIV infection since .10 years,
stable CD4 T-cell counts.500 cells/ml, and plasma viremia,500
HIV RNA copies/ml were also included. Clinical and virological
characteristics of the different cohorts are detailed in Table S1.
Synthetic peptides and peptide-MHC class I multimer
complexes
Epitope mapping was performed using a panel of 192 HPLC-
purified (.80% purity) previously-described optimal epitopes [71].
Confirmation of specificity was achieved based on the HLA class I
genotype of the patients and ICS assays. Peptide-MHC class I
multimers (listed in Table S2) were purchased from ProImmune
(Oxford, UK) except HLA-B*0801-RAKFKQLL, HLA-B*0702-
RPPIFIRRL, HLA-B*0702-TPRVTGGGAM and HLA-B*5701-
TSTLQEQIGW (Table S2) which were produced as described
[72].
Antibodies
The following antibodies were used in different combinations.
CD8-PB, CD8-APCH7, CD3-APCH7, CD45RA-PECy5, PD-1-
FITC, IFN-c-APC, TNF-a-PECy7, and IL-2-PE were purchased
from Becton Dickinson (BD, San Diego, CA), CD4-ECD, CD3-
ECD, CD28-ECD, CD27-APC from Beckman Coulter (Fullerton,
CA, USA), Perforin-FITC (clone B-D48) from Diaclone (Besan-
c¸on, France), CCR7-FITC from R&D Systems (Minneapolis, MN,
USA), 2B4-PECy5.5 and CD160-APC from Biolegend (San
Diego, CA, USA).
Functional Avidity of HIV-Specific CD8 T cells
PLOS Pathogens | www.plospathogens.org 9 July 2013 | Volume 9 | Issue 7 | e1003423
IFN-c ELISpot assay
ELISPOT assays were performed as per the manufacturer’s
instructions (BD Biosciences). In brief, 26105 cryo-preserved
blood mononuclear cells were stimulated with 1 mg of single
peptide or peptide pools in triplicate conditions as described [73].
Media only and staphylococcal enterotoxin B (SEB) were used as
negative and positive controls, respectively. Thresholds for assay
validation and positivity were determined as described [73].
Results are expressed as the mean number of SFU/106 cells from
triplicate assays. Only cell samples with .80% viability after
thawing were analyzed, and only assays with ,50 spot forming
unit (SFU)/106 cells for the negative control and .500 SFU/106
cells after SEB stimulation were considered valid. An ELISpot
result was defined as positive if the number of SFUs was $55
SFU/106 cells and $4-fold the negative control.
Ex vivo analysis of virus-specific CD8 T cells
Cryo-preserved blood mononuclear cells (1–26106) were
stained for dead cells (4uC for 209; Aqua LIVE/DEAD,
Invitrogen) and then stained with appropriately tittered peptide-
MHC class I tetramer complexes at 4uC for 309 in Ca2+-free
media as described [74]. Cells were then washed and directly
stained at 4uC for 209 with the following Abs in various
combinations: CD3, CD8, CD28, CD27, PD-1, 2B4, CD160.
Finally, cells were fixed (CellFix, BD), acquired on an LSRII
SORP (4 lasers) and analyzed using FlowJo 8.8.2 (Tree star Inc,
USA). Analysis and presentation of distributions were performed
using SPICE version 5.1, downloaded from http://exon.niaid.nih.
gov/spice/ [75]. The number of lymphocyte-gated events ranged
between 0.6–16106 in the flow cytometry experiments.
ICS assay
Cryo-preserved blood mononuclear cells (1–26106) were
stimulated for 6 h or overnight in 1 ml of complete media (RPMI
(Invitrogen), 10% fetal bovine serum (FBS; Invitrogen), 100 mg/ml
penicillin, 100 units/ml streptomycin (BioConcept)) in the
presence of Golgiplug (1 ml/ml, BD), anti-CD28 (0.5 mg/ml,
BD) and 1 mg/ml of peptide as described [74]. Staphylococcus
enterotoxin B (SEB; Sigma) stimulation (100 ng/ml) served as
positive control. At the end of the stimulation period, cells were
stained for dead cells (4uC for 209; Aqua LIVE/DEAD,
Invitrogen), permeabilized (RT for 209; Cytofix/Cytoperm, BD)
and then stained at RT for 209 with CD4, CD8, CD3, IFN-c, IL-
2, TNF-a and perforin (clone B-D48). Cells were then fixed
(CellFix, BD), acquired on an LSRII SORP and analyzed using
FlowJo 8.8.2. Analysis and presentation of distributions were
performed using SPICE version 5.1, downloaded from http://
exon.niaid.nih.gov/spice/ [75]. The number of lymphocyte-gated
events ranged between 0.6–16106. With regard to the criteria of
positivity of the ICS, the background in the unstimulated controls
never exceeded 0.03%. An ICS to be considered positive had to
have .0.03% of cytokine-positive cells after subtraction of the
background (media alone) and to be .5 fold higher that the
background.
Determination of CDR3 renewal
The analysis of the CDR3 diversity and renewal was performed
as described [32]. CDR3 renewal corresponds to the percentage of
TCR sequences specific for a given epitope that changed between
two time points. Briefly, blood mononuclear cells were stained
with cognate multimers and anti-CD3, anti-CD8, anti-CD45RA,
and anti-CCR7 mAbs (BD Biosciences). CD45RA+ CCR7+ naı¨ve
and Ag-specific (multimer+) CD8 T cells were directly sorted
(FACSAria, BD Biosciences) in RLT lysis buffer (Qiagen, Hilden,
Germany) containing 20 ng RNA carrier (Roche Diagnostics,
Rotkreuz, Switzerland) and RNA extracted (Qiagen). Then,
cDNA preparation and amplification were performed by using
the SuperSMART PCR cDNA Synthesis Kit according to the
manufacturer’s instructions (Clontech Laboratories, Saint-Ger-
main-en-Laye, France). Amplified cDNA was subjected to TRBV–
TCR-b–chain C region (TRBC) PCR reactions as described [32].
For spectratyping, aliquots of positive samples were mixed with
Genescan-500 ROX size standards and run on an ABI 3130
capillary sequencer (Applied Biosystems, Foster City, CA). The
CDR3 junction (length) was analyzed using the IMGT system as
described [32].
Functional avidity
Peptide stimulations were performed as described above.
Functional avidity of T-cell responses was assessed by performing
limiting peptide dilutions (ranging from 2 mg/ml to 1 pg/ml) in in
vitro assays as described [24]. The peptide concentration required
to achieve a half-maximal IFN-c response (EC50) was determined.
HLA class I genotyping
Four-digit HLA class I genotyping was performed by direct
sequencing methods as described [76]. The data were analyzed
and alleles were assigned using Assign-SBT version 3.5 (Conexio
Genomics, Applecross, Australia).
Statistical analyses
Mann-Whitney and Wilcoxon-matched paired tests were
performed using GraphPad Prism version 6.00 (San Diego, CA).
Analyses of the functional avidity of CD8 T-cell responses were
performed on log10-transformed data using non-parametric tests.
Associations among variables were performed by Spearman test.
Rank correlations matrix and linear regression analysis were
performed after log10 transformation of variables using R software.
Bonferroni corrections for multiple analyses were applied.
Regarding SPICE analyses of the flow-cytometry data, compar-
ison of distributions was performed using a Student’s t-test and a
partial permutation test as described [75]. Furthermore, mixed-
effect linear models were used to assess the evolution of functional
avidity as a function of the time and virus rebound, as described
[39,40]. In brief, let Y_ij be the measured avidity for subject i at
time j (time_ij) and rebound_ij, the covariate coded as 1 if a
patient i is an on-therapy at time j and coded as 0 if not on therapy
(off-therapy). We fitted the following mixed effect linear model:
Y_ij = (b_0+r_i)+(b_1)time_ij+(b_2)rebound_ij+e_ij where b_0 is
the global mean, b_1 the effect of the time on avidity, b_2 the
effect of the virus rebound on avidity, r_i the random effect which
represents the individual deviation from the global intercept and e
ij are independent measurement errors with mean zero. The
interaction between time_ij and rebound_ij was tested.
Supporting Information
Figure S1 Magnitude and qualitative profiles of HIV-
specific CD8 T cells during acute and chronic HIV
infections. A. Associations between the magnitude and the
functional avidity of HIV-specific CD8 T-cell responses from
patients with either acute infection (PHI-B), untreated chronic
progressive (CP-B) or non-progressive (LTNP) HIV infection. B.
Representative flow cytometry examples of the functional profile
of HIV-specific CD8 T cells from patients with acute (PHI-B-07
B*4402-AENLWVTVYY) and chronic progressive (CP-B-1021;
A*2601-EVIPMFSAL) and non-progressive (LTNP-013;
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A*0201-FLGKIWPSYK) HIV infection on the basis of the expression
of IFN-c, TNF-a, IL-2 and perforin. C. Representative flow
cytometry profiles show the identification of HIV-specific CD8 T
cells using relevant peptide-MHC class I multimer complexes
(upper panels) from patients with acute (PHI-B-1037; B*1402-
DRFYKTLRA) or chronic progressive (CP-B-11; A*0201-SLYNTVATL)
and non-progressive (LTNP-2081 A*0201-SLYNTVATL) and CD27
and CD28 expression on HIV-specific CD8 T cells (bottom
panels). D. Representative flow cytometry profiles show the
identification of HIV-specific CD8 T cells using relevant peptide-
MHC class I multimer complexes (left panels) from patients with
acute (PHI-B-1037; B*1402-DRFYKTLRA) or chronic progressive
(CP-B-11; A*0201-SLYNTVATL) and non-progressive (LTNP-2081
A*0201-SLYNTVATL) HIV infection and 2B4, PD-1 and CD160
expression on HIV-specific CD8 T cells (right panels).
(PPTX)
Figure S2 Effect of the combination of Cyclosporin A
with ART and T-cell responses. Analysis of the magnitude
and of the functional avidity of HIV-specific CD8 T-cell responses
in PHI patients treated for one year with either ART alone or
ART + Cycosporin A (CsA).
(PPTX)
Figure S3 TRBV usage and CDR3 size pattern. Example
of TRBV usage and CDR3 size pattern analysis of
B*0702-GPGHKARVL-specific CD8 T cells in patient #1023 at
week 18, 96 and 125. A. Profile of BV families obtained by PCR.
B. CDR3 size profile obtained by genemapper analysis of BV
families. TRB nomenclature is according to Wei et al. Immuno-
genetics (1994). The model used to define CDR3 diversity and
renewal is based on Miconnet et al. J. Immunol. (2011).
(PPTX)
Table S1 Clinical and virological description of the distinct
cohorts of HIV-infected patients.
(PPTX)
Table S2 HIV-derived peptide-MHC class I multimer com-
plexes used in this study.
(PPTX)
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